Company intelligence / Profile preview

Yuyuan Bioscience

Hong Kong, China

Ownership: Private
Development stage: Other

Overview

Yuyuan Bioscience held exclusive development and commercialization rights for nolasiban, an oxytocin receptor antagonist to improve pregnancy rates in IVF, in China. However, the license agreement was terminated in July 2023 due to missed milestones. Nolasiban demonstrated a 5% absolute improvement in ongoing pregnancy rates versus placebo in more than 1,700 women globally, with a favorable safety profile, but Yuyuan never advanced beyond the IND/early clinical stage in China[3][4][6][8].

Therapeutic areas: Women's Health
Modalities: Small molecule
Industry: Biotech

Partnerships

ObsEva

Beyond the preview

Go deeper on Yuyuan Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yuyuan Bioscience.

Explore the full profile